Biotech news for Monday, May 25, 2026, ranked by our 5-dimension investment framework — regulatory, technology, commercial, manufacturing, and narrative.
Immix Biopharma ( IMMX ) traded higher after announcing data from a mid-stage trial for its lead asset, NXC-201, in AL amyloidosis, a rare disease characterized by the accumulation of abnormal light chains in various organs of the body. The company said
Nanobiotix ( NBTX ) said it plans to raise about €75M ($87M) through a global follow-on offering , subject to market conditions. The offering includes a public sale of American Depositary Shares (ADSs) in the U.S., and a sale of ordinary shares and pre-funded…
Relay Therapeutics ( RLAY ) announced pricing of a public offering of 22.92M shares of its common stock at $12.00 per share. The gross proceeds from this offering are anticipated to be around $275M. The company also allowed underwriters to buy an